Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Neurokinin(1) receptor antagonists as potential antidepressants
Autore:
Stout, SC; Owens, MJ; Nemeroff, CB;
Indirizzi:
Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Lab Neuropsychopharmacol, Atlanta, GA 30322 USA Emory Univ Atlanta GA USA 30322 uropsychopharmacol, Atlanta, GA 30322 USA
Titolo Testata:
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
, volume: 41, anno: 2001,
pagine: 877 - 906
SICI:
0362-1642(2001)41:<877:NRAAPA>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
CENTRAL-NERVOUS-SYSTEM; SUBSTANCE-P RECEPTOR; TACHYKININ NK1 RECEPTOR; CORTICOTROPIN-RELEASING-FACTOR; DORSAL PERIAQUEDUCTAL GRAY; VENTRAL TEGMENTAL AREA; RAT LOCUS-COERULEUS; K-BINDING-SITES; INDUCED C-FOS; HUMAN-BRAIN;
Keywords:
substance P; NK1; anxiolytic; antidepressant; MK-869; neuropeptide;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
176
Recensione:
Indirizzi per estratti:
Indirizzo: Stout, SC Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Lab Neuropsychopharmacol, Atlanta, GA 30322 USA Emory Univ Atlanta GA USA 30322 harmacol, Atlanta, GA 30322 USA
Citazione:
S.C. Stout et al., "Neurokinin(1) receptor antagonists as potential antidepressants", ANN R PHARM, 41, 2001, pp. 877-906

Abstract

Selective, nonpeptide antagonists for tachykinin receptors first became available ten years ago. Of the three known tachykinin receptors, drug development has focused most intensively on the substance P-preferring receptor, neurokinin(1) (NK1). Although originally studied as potential analgesic compounds, recent evidence suggests that NK1 receptor antagonists may possess antidepressant and anxiolytic properties. If confirmed by further controlled clinical studies, this will represent a mechanism of action distinct fromall existing antidepressant agents. As reviewed in this chapter, the existing preclinical and clinical literature is suggestive of, but not conclusive, concerning a role of substance P and NK1 receptors in the pathophysiology of depression and/or anxiety disorders. The ongoing clinical trials with NK1 receptor antagonists have served as an impetus for much needed, basic research in this field.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 17:28:15